Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 9/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 17/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545722 | 1.00 | FGFR2 (0.51) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL16060872 | 0.88 | FGFR1 (0.47) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL15412605 | 0.86 | FGFR1 (0.58) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL15413227 | 0.82 | FGFR4 (0.69) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL29545548 | 0.82 | FGFR2 (0.52) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL20733977 | 0.82 | FGFR2 (0.52) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL23328282 | 0.82 | FGFR1 (0.53) | FGFR2FGFR4FGFR1 | |
| SCHEMBL16071547 | 0.82 | FGFR2 (0.53) | FGFR2FGFR4FGFR1FGFR3EGFR | |
| SCHEMBL23328715 | 0.81 | FGFR1 (0.38) | FGFR2FGFR4FGFR1 | |
| SCHEMBL23328287 | 0.81 | FGFR1 (0.55) | FGFR2FGFR4FGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019029541-A1 | FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-02-14 | — | — | WO | disclosed |